BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX)

BMO Capital analyst Evan Seigerman reiterated a Buy rating on Vertex Pharmaceuticals today and set a price target of $600.00.

According to TipRanks, Seigerman is a 5-star analyst with an average return of 10.9% and a 57.95% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Amgen, and Eli Lilly & Co.

In addition to BMO Capital, Vertex Pharmaceuticals also received a Buy from Barclays’s Eliana Merle in a report issued today. However, on the same day, Canaccord Genuity maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).